Literature DB >> 20600611

Angiotensin-converting enzyme (ACE) inhibitors exacerbate histological damage and motor deficits after experimental traumatic brain injury.

Elizabeth Harford-Wright1, Emma Thornton, Robert Vink.   

Abstract

Angiotensin-converting enzyme (ACE) inhibitors are widely used as blood pressure medications in hypertensive individuals. However, ACE inhibitors also play an integral role in the breakdown of neuronal substance P, which has been recently implicated in the development of functional deficits following traumatic brain injury (TBI). The present study therefore examined the effects of ACE inhibitors on histological and motor outcome following TBI. Male Sprague-Dawley rats were treated with Captopril, Enalapril or equal volume saline for 7 days prior to the induction of diffuse TBI using the impact acceleration model. At 5h post-injury, animals administered Captopril demonstrated significantly increased substance P immunoreactivity compared to vehicle controls (p<0.01), and increased dark cell change that persisted to 7 days post-trauma. Captopril also resulted in exacerbated motor deficits compared to vehicle treated animals (p<0.05) as assessed by the rotarod test over a 7-day post-traumatic period. Administration of the alternative ACE inhibitor, Enalapril, likewise exacerbated motor deficits, confirming a class effect of ACE inhibitors rather than a compound effect specific to Captopril. We conclude that ACE inhibitors are deleterious to outcome following TBI, presumably by impairing the degradation of substance P and increasing substance P mediated neuronal injury. 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20600611     DOI: 10.1016/j.neulet.2010.06.044

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  15 in total

1.  A substance P antagonist improves outcome in female Sprague Dawley rats following diffuse traumatic brain injury.

Authors:  Frances Corrigan; Anna Leonard; Mounir Ghabriel; Corinna Van Den Heuvel; Robert Vink
Journal:  CNS Neurosci Ther       Date:  2012-06       Impact factor: 5.243

2.  Treatment of traumatic brain injury in rats with N-acetyl-seryl-aspartyl-lysyl-proline.

Authors:  Yanlu Zhang; Zheng Gang Zhang; Michael Chopp; Yuling Meng; Li Zhang; Asim Mahmood; Ye Xiong
Journal:  J Neurosurg       Date:  2016-05-20       Impact factor: 5.115

Review 3.  Inflammation in acute CNS injury: a focus on the role of substance P.

Authors:  F Corrigan; R Vink; R J Turner
Journal:  Br J Pharmacol       Date:  2015-05-12       Impact factor: 8.739

4.  Walker 256 tumour cells increase substance P immunoreactivity locally and modify the properties of the blood-brain barrier during extravasation and brain invasion.

Authors:  Kate M Lewis; Elizabeth Harford-Wright; Robert Vink; Alan J Nimmo; Mounir N Ghabriel
Journal:  Clin Exp Metastasis       Date:  2012-05-19       Impact factor: 5.150

Review 5.  Animal modelling of traumatic brain injury in preclinical drug development: where do we go from here?

Authors:  Niklas Marklund; Lars Hillered
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

6.  Development of a stretch-induced neurotrauma model for medium-throughput screening in vitro: identification of rifampicin as a neuroprotectant.

Authors:  Isabel López-García; Domokos Gerő; Bartosz Szczesny; Petra Szoleczky; Gabor Olah; Katalin Módis; Kangling Zhang; Jungling Gao; Ping Wu; Lawrence C Sowers; Doug DeWitt; Donald S Prough; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2016-11-15       Impact factor: 8.739

7.  Characterisation of Walker 256 breast carcinoma cells from two tumour cell banks as assessed using two models of secondary brain tumours.

Authors:  Kate M Lewis; Elizabeth Harford-Wright; Robert Vink; Mounir N Ghabriel
Journal:  Cancer Cell Int       Date:  2013-02-01       Impact factor: 5.722

8.  Blocking neurogenic inflammation for the treatment of acute disorders of the central nervous system.

Authors:  Kate Marie Lewis; Renée Jade Turner; Robert Vink
Journal:  Int J Inflam       Date:  2013-05-29

9.  Treatment with the NK1 antagonist emend reduces blood brain barrier dysfunction and edema formation in an experimental model of brain tumors.

Authors:  Elizabeth Harford-Wright; Kate M Lewis; Mounir N Ghabriel; Robert Vink
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

10.  The role of substance p in ischaemic brain injury.

Authors:  Renée J Turner; Robert Vink
Journal:  Brain Sci       Date:  2013-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.